Scientific Agenda

Wednesday, 27 June, 2012

12:30

Expert discussion (by invitation only): Metastatic pancreatic cancer Scientific committee and selected experts

Session I: Selected abstracts I

Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD

15:00

Welcome and introduction
Congress Chairs Mario Dicato, MD and Eric Van Cutsem, MD, PhD

15:05

Presentation of selected abstracts

International Experts' Consensus for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer
F. Bonnetain, et al., O-0001

A Phase2 adjuvant trial of GI-4000 plus gemcitabine vs. gemcitabine alone in Ras + patients with resected pancreas cancer: R1 subgroup analysis
D. Richards, et al., O-0002

Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC)
E. Mitchell, et al., O-0003

Updated analysis of phase II study of the anti-IGF-1R antibody MK-0646 with gemcitabine +/- erlotinib for advanced pancreatic cancer (APC)
R. Shroff, et al., O-0004

FOLFIRI.3 alternating with gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma: The randomized multicenter AGEO phase II trial FIRGEM
I. Trouilloud, et al., O-0005

Session II: Cancer of the pancreas and bile ducts

Chairs: Jordan D. Berlin, MD and Mario Dicato, MD

16:00

How to improve surgical results for pancreatic cancer?
Markus W. Büechler, MD

16:20

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Manuel Hidalgo, MD, PhD

16:40

Why is pancreatic cancer so thrombogenic?
Mario Dicato, MD

17:00

How can a borderline resectable or non-resectable pancreatic cancer become resectable? Chemo or chemoradiotherapy?
Jordan D. Berlin, MD

17:20

Presentation of selected abstracts

Dose escalation to rash for erlotinib plus gemcitabine in patients with metastatic pancreatic cancer: The phase II RACHEL (BO21128) study
E. Van Cutsem, et al., O-0006

Exploratory serum biomarker analyses from BO21129, a phase II study of erlotinib in second-line pancreatic cancer: Potential role of amphiregulin
M. Ducreux, et al., O-0007

Randomized phase II study of gemcitabine + TH-302 vs gemcitabine in previously untreated patients with unresectable locally advanced and metastatic pancreatic cancer (PAC)
D. Ryan, et al., O-0008

17:50

Debate: This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma

Pro
Marc Ychou, MD, PhD

Contra
Margaret A. Tempero, MD

18:20

New agents in pancreatic cancer
Eileen M. O’Reilly, MD

18:40

Should patients with resected bile duct cancer receive an adjuvant treatment?
Juan W. Valle, MD

19:00

Adjourn

CLOSED SESSION (by invitation only)

Parallel with Session II: Cancer of the pancreas and bile ducts

16:00

Strategy of national and international clinical trial groups

19:00

Adjourn closed session

Thursday, 28 June 2012

CLOSED SESSION (by invitation only)

Parallel with Session III: Meet the expert concurrent presentations and Session IV: Cancer of the liver

8:00

How to go forward with translational research in GI Cancer

Session III: Meet the expert concurrent presentations

8:00

Anal cancer
Robert Glynne-Jones, MBBS, FRCR, FRCP and Karin Haustermans, MD, PhD

Cholangiocarcinoma and gall bladder cancer
Juan W. Valle, MD

Supportive cancer: Management of anemia and emesis – guidelines
Mario Dicato, MD

GIST
John R. Zalcberg, MD, PhD, FRACP

Challenges and limitations in rectal cancer
Chris Cunningham, MD, FRCSEd and Andre D’Hoore, MD, PhD

Medical writing
Daniel G. Haller, MD

9:00

Session adjourns

Session IV: Cancer of the liver

Chairs: Jordi Bruix, MD, PhD and Wolff Schmiegel, MD, PhD

9:00

Presentation of selected abstract

Second line therapy in hepatocellular carcinoma (HCC): A randomized controlled phase 2 trial (RCT) with tivantinib (ARQ 197)
C. Porta, et al., O-0009

9:10

Pathologic and molecular changes occurring in HCC
Josep M. Llovet, MD

9:30

Is a biopsy in a liver nodule/HCC always needed before starting a treatment?
Jordi Bruix, MD

9:45

How to decide in the jungle of local/regional therapies for HCC?
Chris Verslype, MD, PhD

10:05

New agents on the horizon in HCC
Ghassan K. Abou-Alfa, MD

10:20

Keynote lecture 1: Genetic screening for colorectal cancer: For whom and how? Judith Balmaña, MD

10:50

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors

Chairs: Roberto Labianca, MD and John R. Zalcberg, MD, PhD, FRACP

11:20

Whom to treat and how long to treat after resection of GIST
John R. Zalcberg, MD, PhD, FRACP

11:35

What should a pathologist report in a NET?
Aurel Perren, MD

11:55

Medical treatment of NET: Somatostatin anologues, biological and/or chemotherapy
Martyn E. Caplin, BSc Hons, DM, FRCP

12:15

Efficacy and toxicity of peptide receptor targeted radiopeptide therapy
Martin A. Walter, MD

12:35

Discussion

12:45

Session adjourns

13:00

Concurrent luncheon symposia begin

14:30

Concurrent luncheon symposia adjourn

Session VI: Esophageal cancer

Chairs: Arnaud D. Roth, MD and Thomas Seufferlein, MD, PhD

14:45

Treatment of Barrett’s esophagus: Update on new endoscopic modalities
Ralf Kiesslich, MD, PhD

15:05

Is surgery alone still an option in esophageal cancer? For whom?
Christophe Mariette, MD, PhD

15:20

Debate: Which neoadjuvant treatment in GEJ?

Pro chemotherapy
Philippe Rougier, MD, PhD

Pro chemoradiotherapy
Karin Haustermans, MD, PhD

15:50

Tumor board: Discussion and cases
Moderator: Philippe Rougier, MD, PhD
Panel: Karin Haustermans, MD, PhD; Ralf Kiesslich, MD, PhD; Christophe Mariette, MD, PhD

16:10

Travel Grant Award Ceremony

16:15

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session VII: Gastric cancer

Chairs: Andrés Cervantes, MD, PhD and Jin Li, MD, PhD

16:45

Carcinogenesis in gastric cancer
Fatima Carneiro, MD, PhD

17:05

How important is experience/volume in gastric cancer surgery?
Cornelis J. H. van de Velde, MD, PhD

17:25

Is a laparoscopy part of the initial staging?
Cornelis J. H. van de Velde, MD, PhD

17:35

Should all patients be treated with adjuvant and/or neoadjuvant treatment?
Arnaud D. Roth, MD

17:50

What is the reference cytotoxic regimen in advanced gastric cancer?
Florian Lordick, MD, PhD

18:05

Presentation of selected abstracts

Evaluation of MET-pathway biomarkers in a phase 2 study of rilotumumab plus epirubicin, cisplatin, and capecitabine in gastric/esophagogastric junction cancer
M. Schupp, et al., O-0011

Prognostic factors of overall survival (OS) in previously treated advanced gastric cancer (AGC): Analysis of the Phase 3 GRANITE-1 Trial
E. Van Cutsem, et al., O-0012

18:25

Targeted agents in gastric cancer
Manish A. Shah, MD

18:45

Are all gastric cancers identical?
Manish A. Shah, MD

19:00

Session adjourns

19:15

Evening symposium begins

20:45

Evening symposium adjourns

Friday, 29 June 2012

Session VIII: Meet the expert concurrent presentations

Parallel with Session IX: Screening and prevention for GI cancer – ESDO symposium, Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer, and Session XI: Presentation of selected abstracts

8:00

Peritoneal metastases
Santiago González-Moreno, MD, PhD

Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, PhD, FRCP

Treatment of elderly patients with GI cancer
Demetris Papamichael, MB, BS, FRCP

ESSO session on surgery: Liver resection and ablation techniques
Graeme J. Poston, MD and René Adam, MD

9:00

Session adjourns

Session IX: Screening and prevention for GI cancer – ESDO symposium

Parallel with Session VIII: Meet the expert concurrent presentations, Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer, and Session XI: Presentation of selected abstracts

Chairs: Nadir Arber, MD, MSc, MHA and Thomas Seufferlein, MD, PhD

8:00

Screening for colon cancer
Wolff Schmiegel, MD, PhD

Helicobacter Pylori and gastric cancer
Thomas Seufferlein, MD, PhD

Chemoprevention for GI cancer
Nadir Arber, MD, MSc, MHA

9:30

Session adjourns

Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX: Screening and prevention for GI cancer – ESDO symposium, and Session XI: Presentation of selected abstracts

Chairs: Fortunato Ciardiello, MD, PhD and Alberto Sobrero, MD

8:00

Is DFS, RR or survival the best endpoint in colorectal cancer?
Marc Buyse, ScD

Which difference should we target?
Alberto Sobrero, MD

Pharmacodynamic endpoints
Fortunato Ciardiello, MD, PhD

Discussion

9:30

Session adjourns

Session XI: Selected abstracts II

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX: Screening and prevention for GI cancer – ESDO symposium, and Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer

Chairs: Michel Ducreux, MD, PhD and John L. Marshall, MD

8:00

Presentation of selected abstracts

Improved early prediction of individual prognosis for patients with metastatic colorectal cancer: Joint modeling of tumor shrinkage with volume data
V. Heinemann, et al., O-0013

Effect of post-protocol anti-EGFR mAb therapy on survival outcomes in patients with wild-type KRAS mCRC treated with panitumumab plus chemotherapy
J.Y. Douillard, et al., O-0014

Survival according to prognostic risk factors in patients receiving first-line chemotherapy plus cetuximab in the CRYSTAL and OPUS studies
C.H. Köhne, et al., O-0015

Cetuximab combined with infusional 5-fluorouracil/folinic acid and oxaliplatin in metastatic colorectal cancer: Pooled analysis of COIN and OPUS study data
J. Taïeb, et al., O-0016

Randomized phase II study evaluating UFOX plus cetuximab versus FOLFOX4 plus cetuximab as first-line therapy in metastatic colorectal cancer: FUTURE
J.Y. Douillard, et al., O-0017

Efficacy and safety of bevacizumab in metastatic colorectal cancer: Overall and subgroup analyses of pooled data from randomized controlled trials
H. Hurwitz, et al., O-0018

Session XII: Special EONS nurses’ symposium: Management of patients with rectal cancer

Parallel with Session XIII: ESMO session: Focus on young medical oncologist

Chair: Lena Sharp, RN, PhD

9:00

Professional communication for increased patient safety in cancer care
Lena Sharp, RN, PhD

9:20

Biomarkers in digestive oncology - challenges or pitfalls for patients
Liesbeth Lemmens, MSc, RN

9:40

Long-term effects of surgery and radiotherapy for colorectal cancer and quality of life
Rachel Haigh, RN, MSc, PGDip, BSc

10:00

The role of patients groups and advocacy groups in colon cancer
Jola Gore-Booth

10:20

Discussion

Session XIII: ESMO session: Focus on young medical oncologist

Parallel with Session XII: Special EONS nurses’ symposium: Management of patients with rectal cancer

Chair: Roberto Labianca, MD

9:00

Why invest in Young Medical Oncologists?
Roberto Labianca, MD

9:10

Novel predictive factors for patients treated with anti-angiogenetic drugs
Fotios Loupakis, MD, PhD

9:30

Status of the art of predictive factors for anti-EGFR drugs
Andrea Sartore-Bianchi, MD

9:50

Presentation of selected abstract Single Nucleotide Polymorphisms (SNP’s) in the p53, SMAD7 and TGFBR1 genes associated with advanced colorectal cancer in Caucasian patients compared to healthy controls
G. Mahon, et al., O-0027

10:00

Keynote lecture 2: Should we take aspirin and/or prescribe it to our patients?
Timothy Bishop, MD

10:30

Break and poster viewing Abstracts to be presented: Clinical/basic CRC abstracts

Session XIV: Multimodality therapy for rectal cancer

Chairs: Karin Haustermans, MD, PhD and Bernard Nordlinger, MD

11:00

Imaging in rectal cancer: What is mandatory for optimal staging?
Gina Brown, MD

11:20

Organ sparing-surgery in rectal cancer: How important is it? How can we progress with it?
Andre D’Hoore, MD, PhD

11:35

Is local excision by TEMS adequate treatment for early rectal cancer?
Chris Cunningham, MD

11:50

Which neoadjuvant treatment in rectal cancer?
Robert Glynne-Jones, MBBS, FRCR, FRCP

12:10

Rectal cancer: what is next in the field of radiotherapy?
Karin Haustermans, MD, PhD

12:25

Do we need post-operative chemotherapy in patients with pathologic CR to neoadjuvant therapy?
Philippe Rougier, MD, PhD

12:40

Presentation of selected abstracts

Severe fluoropyrimidines toxicities: A simple and effective way to avoid them. Screen effectively for DPD deficiencies
M. Boisdron-Celle, et al., O-0019

Personalized treatment planning of stage II and IIIA colon cancer patients using genomic classifiers (ColoPrint/ MSI-Print)
R. Salazar, et al., O-0025

13:00

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XV: Highlights in cancer

Chairs: Nadir Arber, MD, MSc, MHA

15:00

Keynote lecture 3: Gastric cancer surgery in Japan: Why is it different?
Takeshi Sano, MD

15:30

Keynote lecture 4: What can we afford: Health economics in GI cancer
John L. Marshall, MD

16:00

Keynote lecture 5: Priorities for clinical research in GI cancer
Daniel G. Haller, MD

16:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XVI: Hot topics in colon cancer

Chair: Salvatore Siena, MD

17:00

Are we making progress in the molecular taxonomy of colon cancer?
Sabine Tejpar, MD, PhD

17:20

Should MSI be determined in all patients with stage II and III colon cancer patients?
Ramon Salazar, MD

17:35

Is gene signature based selection ready for clinical use?
Pierre Laurent-Puig, MD, PhD

17:50

Presentation of selected abstract

Adjuvant FOLFOX4 +/- cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from the PETACC8 intergroup trial
J. Taieb, et al., O-0028

18:00

How to treat a patient with stage III colon cancer in 2012
Thierry André, MD

18:20

Are all KRAS mutations identical?
Salvatore Siena, MD

Session XVII: Poster discussion session

18:40

Poster discussion session I on colon cancer (PD-0001 to PD-0009)
Thomas Grüenberger, MD

18:50

Poster discussion session II on colon cancer (PD-0010 to PD-0014)
Nadir Arber, MD, MSc, MHA

19:00

Poster discussion session III on colon cancer (PD-0015 to PD-0025, PD-0034)
Dirk Arnold, MD

19:10

Poster discussion on non-colorectal cancer (PD-0026 to PD-0032, PD-0035)
Margaret A. Tempero, MD

19:20

Session adjourns

Saturday, 30 June 2012

Session XVIII: ESMO Consensus Conference: Interactive Session on Colorectal Cancer Guidelines

Chairs: Hans-Joachim Schmoll, MD, PhD and Andrés Cervantes, MD, PhD

8:30

Introduction to ESMO consensus conference - Why do we need guidelines?
Andrés Cervantes, MD, PhD

8:45

A clinical case presentation on localized rectal cancer
Noelia Tarazona Llavero, MD

8:55

Discussant
Vicenzo Valentini, MD

9:10

A clinical case presentation on advanced colon cancer (first and second line therapy)
Alexander Stein, MD

9:25

Discussants
Hans-Joachim Schmoll, MD, PhD and Andrés Cervantes, MD, PhD

9:40

Break

Session XIX: Metastatic colorectal cancer

Chairs: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD

10:10

What is the best cytotoxic backbone for biologicals?
Jean-Yves Douillard, MD, PhD

10:30

Which biological targeted agent and for whom?
Michel Ducreux, MD, PhD

10:50

Maintenance treatment or stop and go: What is the standard?
Aimery de Gramont, MD, PhD

11:00

Presentation of selected abstracts

Bevacizumab + chemotherapy beyond first progression in metastatic colorectal cancer patients previously treated with bevacizumab-based therapy: TML study subgroup findings
T. André, et al., O-0020

Randomised phase III study of bevacizumab + chemotherapy beyond progression in bevacizumab-treated patients with metastatic colorectal cancer: TML study KRAS subgroup findings
E. Van Cutsem, et al., O-0021

11:20

Molecular markers beyond KRAS for anti-EGFR targeted agents and markers for angiogenesis inhibitors – What is new?
Heinz-Josef Lenz, MD

11:35

Presentation of selected abstracts

X-PECT study results: A phase III randomized study of perifosine plus capecitabine vs. placebo plus capecitabine in refractory mCRC patients
J. Bendell, et al., O-0022

Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)
A. Sobrero, et al., O-0023

Phase 2 randomized, noncomparative, open-label study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM)
C. Pericay, et al., O-0024

12:05

New drugs on the horizon for CRC in 2012
Eric Van Cutsem, MD, PhD

12:25

New targets in gastrointestinal cancer
Josep Tabernero, MD, PhD

12:45

Session adjourns

13:00

Concurrent luncheon symposia and ESO Cancer Observatory begin

14:30

Concurrent luncheon symposia and ESO Cancer Observatory adjourn

Session XX: Surgery and peritoneal and liver metastases

Chairs: Mario Dicato, MD and Graeme J. Poston, MD

14:45

Presentation of ESSO Award

Prognostic impact of DNA mismatch repair status and BRAFV600E mutations in stage III colon cancer patients treated in a phase III study of adjuvant FOLFOX alone or combined with cetuximab: NCCTG N0147
F. Sinicrope, et al., O-0029

14:50

Presentation of selected abstract

Long term survival data from EORTC study 40983: Perioperative chemotherapy for resectable live metastases from colorectoal cancer
B. Nordlinger, et al., O-0030

15:00

Surgery for liver metastases: How far should the surgeon go?
Thomas Grüenberger, MD

15:20

The multimodal treatment of liver metastases: Frequently asked questions
Bernard Nordlinger, MD

15:40

Multidisciplinary management of peritoneal carcinomatosis from colorectal cancer: New perspectives
Marcello Deraco, MD

16:00

Liver directed therapy – When and how? (Selective radiotherapy, drug eluting beads or intrahepatic chemotherapy)
Volker Heinemann, MD, PhD

Session XXI: Report on expert discussion

16:20

Presentation of outcome of expert discussion on metastatic pancreatic cancer
Mario Dicato, MD and Eric Van Cutsem, MD, PhD

16:40

Adjourn